Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Society of Clinical Oncology Annual Meeting taking place May 29 - June 2 in Chicago, Illinois.

"We are pleased to share data from this important subset of r/r WM patients for whom there are no approved therapies and remaining options are restricted to salvage therapies which provide limited benefit. It is important to note that approximately 60% of drugs used for all WM patients are considered salvage therapies," said Jarrod Longcor, chief operating officer of Cellectar. "The safety and efficacy of iopofosine observed to date are highly encouraging and underscore its potential to address a significant unmet need for patients who progress after BTK inhibitors. We believe these findings further support the potential for iopofosine to emerge as a differentiated therapeutic option in the post-BTKi setting as early as the second line of treatment."